Finance

Lists
600535:SHA
Tasly Pharmaceutical Group Co Ltd
14,04 CN¥
-0,35%
(-0,050) 1D
16 հոկ, 15:00:00 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600535...
Open
14,18 CN¥
High
14,35 CN¥
Low
13,92 CN¥
Mkt. cap
21,05 մլրդ
Avg. vol.
11,45 մլն
Volume
15,72 մլն
Dividend
2,42%
Quarterly dividend
0,09 CN¥
Ex-dividend date
29 մյս, 2026 թ.
P/E ratio
17,15
52-wk high
16,24 CN¥
52-wk low
12,90 CN¥
EPS
0,82 CN¥
Shares outstanding
1,51 մլրդ
No. of employees
11 հզր
Open
14,18 CN¥
High
14,35 CN¥
Low
13,92 CN¥
Mkt. cap
21,05 մլրդ
Avg. vol.
11,45 մլն
Volume
15,72 մլն
Dividend
2,42%
Quarterly dividend
0,09 CN¥
Ex-dividend date
29 մյս, 2026 թ.
P/E ratio
17,15
52-wk high
16,24 CN¥
52-wk low
12,90 CN¥
EPS
0,82 CN¥
Shares outstanding
1,51 մլրդ
No. of employees
11 հզր
News stories
From web sources and news partners
Profile
Tasly is a Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange. In 2009, Chinese pharmacologist Li Lianda claimed that a key product made by Tasly was unsafe. Tasly sued Li in 2013, alleging that Li's claim was baseless and was motivated by his financial and employment relations with Guangzhou Pharmaceutical, a direct competitor of Tasly. In September 2014, the Tianjin High People's Court ruled in favour of Tasly and ordered Li to issue an apology and pay Tasly 300,000 yuan in compensation. In February 2017, Tasly announced plans to form a joint venture with American multi-level marketing company Herbalife. Wikipedia
About Tasly Pharmaceutical Group Co Ltd
CEO-
Employees10,6 հզր
Founded1994
Headquarters-
Sector-
Websitetasly.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
2,02 մլրդ
1,93 մլրդ
2,16 մլրդ
2,04 մլրդ
Cost of goods sold
684,07 մլն
659,71 մլն
623,69 մլն
654,28 մլն
Cost of revenue
684,07 մլն
659,71 մլն
623,69 մլն
654,28 մլն
Research and development expenses
210,48 մլն
132,23 մլն
191,62 մլն
102,48 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
844,05 մլն
787,37 մլն
874,15 մլն
656,33 մլն
Operating expense
1,06 մլրդ
979,15 մլն
1,08 մլրդ
801,23 մլն
Total operating expenses
1,74 մլրդ
1,64 մլրդ
1,70 մլրդ
1,46 մլրդ
Operating income
281,20 մլն
286,94 մլն
462,71 մլն
580,75 մլն
Other non operating income
-7,57 մլն
-6,11 մլն
-733,75 հզր
-232,24 հզր
EBT including unusual items
248,13 մլն
192,46 մլն
461,52 մլն
584,82 մլն
EBT excluding unusual items
280,97 մլն
289,16 մլն
472,69 մլն
588,33 մլն
Income tax expense
45,36 մլն
123,68 մլն
96,97 մլն
64,84 մլն
Effective tax rate
18,28%
64,26%
21,01%
11,09%
Other operating expenses
1,56 մլն
53,20 մլն
17,23 մլն
42,82 մլն
Net income
209,68 մլն
120,59 մլն
370,24 մլն
522,44 մլն
Net profit margin
10,37%
6,26%
17,10%
25,66%
Earnings per share
-
-
-
-
Interest and investment income
14,77 մլն
14,84 մլն
14,04 մլն
11,58 մլն
Interest expense
-7,28 մլն
-5,44 մլն
-3,33 մլն
-5,30 մլն
Net interest expenses
7,49 մլն
9,39 մլն
10,71 մլն
6,29 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
380,28 մլն
380,23 մլն
555,99 մլն
663,57 մլն
Gain or loss from assets sale
5,21 մլն
-8,61 մլն
-
-409,04 հզր
AI content may include mistakes. Learn more
Google Apps